29–30 october 2019 hyderabad, india€¦ · at the hyderabad international convention centre...

29–30 OCTOBER 2019 HYDERABAD, INDIA

@THEUNION_TBLH @THEUNIONLUNGHEALTH WORLDLUNGHEALTH.ORG #TBSCIENCE

The Union is pleased to host the second annual TBScience pre-conference, taking place on the eve of the 50th Union World Conference on Lung Health. This is an official event entirely devoted to basic and translational TB research.

TBScience brings together scientists from microbiology, immunology, molecular biology, pharmacology, epidemiology and mathematical modelling to present and discuss recent findings on TB transmission, infection and disease. Additional focus is also given to the development of better vaccines, new drugs and diagnostics for TB.

THANK YOU TO OUR SUPPORTERS

TBScience 2019 is organised by The Union in proud partnership with the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership (EDCTP) and the American Thoracic Society (ATS).

WELCOME TO TB SCIENCE 2019

CONTENTS

04 GENERAL INFORMATION

05 TUESDAY 29 OCTOBER OVERVIEW OF EVENTS

06 TUESDAY 29 OCTOBER MORNING SESSION

07 TUESDAY 29 OCTOBER AFTERNOON SESSION

08 WEDNESDAY 30 OCTOBER OVERVIEW OF EVENTS

10 WEDNESDAY 30 OCTOBER MORNING SESSION

11 WEDNESDAY 30 OCTOBER AFTERNOON SESSION

12 POSTER SESSIONS OVERVIEW OF EVENTS

14 POSTERS NEW DIAGNOSTICS TO REACH THE MISSING MILLIONS

16 POSTERS PREVENT INFECTION OR PREVENT DISEASE?

17 POSTERS NEW STRATEGIES IN TB

THERAPEUTICS: IT’S TIME TO BREAK THE MOULD!

20 POSTERS BACTERIAL EVOLUTION

22 POSTERS MAP

E D C T P

Mark Hatherill TBScience 2019 International Co-ChairFrank Cobelens TBScience 2019 Associate Co-Chair Manjula Singh TBScience 2019 Local Co-ChairTom H. M. Ottenhoff MemberClaudia Denkinger MemberBouke De Jong MemberDavid Lewinsohn MemberEric Nuermberger Member Payam Nahid Member Anete Trajman Member

TBSCIENCE 2019 SCIENTIFIC COMMITTEE MEMBERS

FREE WIFI NETWORK TBSCIENCE PASSWORD TBSCIENCE2019

ABSTRACT BOOK All TBScience abstracts will be published in a supplement of the International Journal of Tuberculosis and Lung Disease (IJTLD) and shared on our website at the end of the Union World Conference. The abstract book is open access and available to all interested parties.

POSTERS All posters will be displayed during the entirety of the conference. We encourage delegates to view the posters during coffee and tea breaks and lunch.

Posters will be arranged according to the session theme. Presenters will present their poster during dedicated viewing sessions.

PHOTOGRAPHY CONSENT By entering the event premises, delegates give their permission to be photographed or recorded by official photographers, videographers and attending media of TBScience. Delegates consent to their images and video being reproduced for subsequent use in the media, webcasts, internal and external promotional purposes, advertising and inclusion on websites and social media. Images are shared publicly with open access for use.

04 TBSCIENCE 2019

CONFERENCE EMBARGO POLICY In the case of TBScience 2019, as with most scientific or medical conferences, all conference abstracts are released to media under a strict embargo policy.

All oral abstracts are embargoed until the time and date of the start of the session in which they are delivered, or during a press conference — whichever comes first.

All poster abstracts are embargoed until 08.30 India Standard Time on Tuesday 29 October.

All delegates, presenters and media are asked to respect this policy.

CERTIFICATE OF PRESENTATION Delegates who wish to receive a certificate of presentation for TBScience should send their request to [email protected] after the conference ends.

FOOD AND BEVERAGES Coffee and tea breaks and lunch will be served adjacent to the session hall on both conference days.

TRANSPORTATION Transportation from TBScience 2019 to the Union World Conference Opening Ceremony at the Hyderabad International Convention Centre (HICC) will be provided for delegates registered for the full conference.

GENERAL INFORMATION TUESDAY 29 OCTOBER OVERVIEW OF EVENTS

TIME TITLE CHAIRS

07.00 – 08.30 Registration

08.30 – 10.00 New diagnostics to reach the missing millions Claudia Denkinger, Urvashi B. Singh and Anete Trajman

10.00 – 10.25 COFFEE AND TEA BREAK POSTER SESSION

10.25 – 12.30 New diagnostics to reach the missing millions Claudia Denkinger, Urvashi B. Singh and Anete Trajman

12.30 – 13.30 LUNCH BREAK POSTER SESSION

13.30 – 15.00 Prevent infection or prevent disease? Tom Ottenhoff, Vijaya Velluri and David Lewinsohn


15.30 – 17.30 Prevent infection or prevent disease? Tom Ottenhoff, Vijaya Valluri and David Lewinsohn

07TBSCIENCE 2019

TIME TITLE SPEAKER

13.30 – 13.45 Three-year efficacy of M72|AS01E vaccine in African adults withlatent mycobacterium tuberculosis infection

Derek Tait

13.45 – 14.00 Immunogenicity of M72|AS01e vaccine in African adults withlatent mycobacterium tuberculosis infection

Olivier van der Meeren

14.00 – 14.30 Where do we stand: POI (BCGrevacc) and (M72) signalsfrom pivotal trials

Mark Hatherill

14.30 – 15.00 Correlates of protection Thomas Scriba


15.30 – 16.00 Mucosal immunity Helen McShane

16.00 – 16.15 Prevention of infection versus prevention of disease — estimating the potential impact of new tuberculosis vaccines

Richard White

16.15 – 16.30 Experimental investigation of a new tuberculosis vaccine based on recombinant Ag85 TB10 and flic proteins

Vladimir Yeremeev

16.30 –16.45 Transcriptomic responses to preventive therapy for latent tuberculosis infection

Claire Broderick

16.45 – 17.00 Infection with the Beijing genotype of mycobacterium tuberculosis and its interaction with BCG vaccine protection: a case contact cohort study

Ayesha Verrall

17.00 – 17.30 Panel Discussion: Can Mtb be controlled or eradicated by the immune system in the infected human host. What is the evidence for this, how can we collect stronger evidence for or against? Can this be modelled? Panel discussion will be chaired by Marcel Behr

Jason Andrews, MarcelBehr, David Lewinsohnand Frank Cobelens

TUESDAY 29 OCTOBER AFTERNOON SESSION

TIME 13.30 – 17.30 SESSION Prevent infection or prevent disease? CHAIRPERSONS Tom Ottenhoff, Vijaya Valluri and David Lewinsohn

TIME TITLE SPEAKER

08.30 – 08.35 Welcome to TBSCIENCE 2019 Manjula Singh and Mark Hatherill

08.35 – 09.00 The TB Diagnostic pipeline – are we reaching the missing millions? Claudia Denkinger

09.00 – 09.20 Next generation of LAM tests: where to go from here? Emmanuel Moreau

09.20 – 09.40 Quantification of circulating Mtb antigens for a rapid TB detection Tony Hu

09.40 – 10.00 cfDNA+CRISPR: Early, pre-feasibility stage, but this can be transformative

Sharon Wong


10.25 – 10.40 Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and individual participant data meta-analysis

Rishi K Gupta

10.40 – 10.55 Oral swab analysis for diagnosis of adult and pediatric pulmonary tuberculosis

Gerard Cangelosi

10.55 – 11.10 Buccal swab analysis for the diagnosis of tuberculosis in children Roger Calderon

11.10 – 11.25 Diagnostic accuracy of rapid urine Fujifilm SILVAMP TB LAM testing to diagnose tuberculosis among people living with HIV in Ghana

Stephanie Bjerrum

11.25 – 11.40 Heteroresistance among patients with drug-resistant tuberculosis Midori Kato-Maeda

11.40 – 11.55 Xpert MTB|RIF misses more than 50% of rifampicin- resistant TB cases in Eswatini: results of the 2nd national anti-TB drug resistance survey (2017/2018)

Welile Sikhondze

11.55 – 12.30 Panel Discussion: Will we be able to address the two TPPs on non-sputum based tests for diagnosis and triage in the next 5 years? Panel discussion will be chaired by Claudia Denkinger

Emmanuel Moreau, Niaz Banaei, Akos Somoskovi and Karen Heichman


TUESDAY 29 OCTOBER MORNING SESSION

TIME 08.30 – 12.30 SESSION New diagnostics to reach the missing millions CHAIRPERSONS Claudia Denkinger, Urvashi B. Singh and Anete Trajman

06 TBSCIENCE 2019

WEDNESDAY 30 OCTOBER OVERVIEW OF EVENTS

TIME TITLE CHAIRS

08.30 – 10.00 New strategies in TB therapeutics: It’s time to break the mould!

Payam Nahid, Chandrasekaran Padmapriyadarsini and Eric Nuermberger



Payam Nahid, Chandrasekaran Padmapriyadarsini and Eric Nuermberger


13.30 – 15.00 Bacterial Evolution Bouke C. de Jong, Frank Cobelens and Rajni Rani


15.30 – 17.10 Bacterial Evolution Bouke C. de Jong, Frank Cobelens and Rajni Rani

17.10 – 17.50 Shuttle service to the opening ceremony of the 50th Union World Conference on Lung Health (registered delegates only)

11TBSCIENCE 2019

TIME TITLE SPEAKER

08.30 – 08.45 Breaking the mould Michael Hölscher

08.45 – 09.10 Basic research into new bacterial drug targets — overview Anil Koul

09.10 – 09.35 Host-directed therapies — overview Robert Wallis

09.35 – 10.00 Mtb transcriptional profiling as a tool for drug/regimen development A novel PD metric: pre-rRNA measures drug impact on Mtb physiologic state

Nicholas Walter


10.20 – 10.35 Experience using new and repurposed rifampicin-resistant TB drugs in five pregnant patients

Rebecca Acquah

10.35 – 10.50 Trial of Delpazolid (LCB01-0371) to assess early bactericidal activity and exposure response relationships

Lawrence Geiter

10.50 – 11.05 Future preventive therapy regimens against tuberculosis: examining performance requirements in different settings

Juan Vesga

11.05 – 11.20 Sanfetrinem repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis

Santiago Ramon-Garcia

11.20 – 11.35 Preliminary comparative microbiome analysis of pulmonary tuberculosis patients: metatranscriptomics approach

Ambreen Shaikh

11.35 – 11.50 TB knowledgebase: interactive application for extracting knowledge from the tb literature to inform TB drug and vaccine development

Chanchala Kaddi

11.50 – 12.30 Panel Discussion: What do we mean by ‘intelligent drug development’? By ‘intelligently designed regimens’? Using these frameworks, are there potential synergies in combining new Mtb- and host-directed therapies? How should the field measure efficacy of and establish evidence for mixed therapeutic intervention approaches? Panel discussion will be chaired by Rada Savic

Bouke C. de Jong, Nicholas Walter, Robert Wallis and Michael Hölscher


TIME 08.30 – 12.30 SESSION New strategies in TB therapeutics: It’s time to break the mould! CHAIRPERSONS Payam Nahid, Chandrasekaran Padmapriyadarsini and Eric Nuermberger

WEDNESDAY 30 OCTOBER MORNING SESSION

TIME TITLE SPEAKER

13.30 – 13.50 ‘Fit to fly’ – exhaled and expectorated tubercle bacilli Caroline Williams

13.50 – 14.10 ‘Fit to Infect’ – the impact of drugs Edward Nardell

14.10 – 14.30 Role of compensatory evolution in the transmission of MDR-TB Sebastien Gagneux

14.30 – 14.50 Development of tolerance in M. tuberculosis under drug pressure Annelies Van Rie

14.50 – 15.00 Questions and answers


15.30 – 15.45 Characterization of lipid-dependent ‘culture-negative’ tuberculosis

Annelies W Mesman

15.45 – 16.00 A frameshift mutation in glpK gene and the drug-resistant phenotype of mycobacterium tuberculosis

Chuan-Chin Huang

16.00 – 16.15 Inferring transmission from mycobacteriumTuberculosis genomes: identifying new approaches to improve accuracy and robustness

Katharine S. Walter

16.15 – 16.30 Genetic variations of mycobacterium tuberculosis that are associated with tuberculosis transmission

Megan Murray

16.30 – 16.45 Distinct interactions of high and low transmission strains of mycobacterium tuberculosis with host alveolar macrophages shapes their transmission phenotype

Padmini Salgame

16.45 – 17.05 Panel Discussion: Effect of regimen choice on transmission Panel discussion will be chaired by Annelies van Rie

Edward Nardell,Caroline Williams, Annelies Van Rie andSebastien Gagneux

17.05 – 17.10 TBSCIENCE 2019 Conference Closing Frank Cobelens and Grania Brigden

TIME 13.30 – 17.10 SESSION Bacterial Evolution CHAIRPERSONS Bouke C. de Jong, Frank Cobelens and Rajni Rani

WEDNESDAY 30 OCTOBER AFTERNOON SESSION

10 TBSCIENCE 2019

POSTER SESSIONS OVERVIEW OF EVENTS

TUESDAY 29 OCTOBER

08.30 – 10.00 New Diagnostics to reach the missing millions

10.00-10.25 COFFEE AND TEA BREAK POSTER SESSION

10.25 – 12.30 New Diagnostics to reach the missing millions

12.30-13.30 LUNCH BREAK POSTER SESSION

13.30 – 15.00 Prevent infection or prevent disease?


15.30 – 17.30 Prevent infection or prevent disease?

WEDNESDAY 30 OCTOBER




12.30-13.30 LUNCH BREAK POSTER SESSION

13.30 – 15.00 Bacterial Evolution


15.30 – 17.10 Bacterial Evolution

POSTER NUMBER

PRESENTER POSTER TITLE

P01 Fleming, Lure Applying multi-modality artificial intelligence for screening of tuberculosis in a TB high-burden large rural region in China

P02 Mkalira, Khwima Esther Mobile van TB screening services for active TB case finding in two districts Blantyre and Nsanje in Malawi

P03 Ametembun, Maria Goretti

Abdominal tuberculosis among young adult diabetes melitus type ii (pancreas ultrasound finding)

P04 Nash, Madlen Deep learning computer-aided radiography reading for tuberculosis: a diagnostic accuracy study from a tertiary hospital in India

P05 Mohr-Holland, Erika Gender and rr-TB treatment mortality: increased early mortality among women in the setting of universal drug susceptibility testing in Khayelitsha South Africa

P06 Swartz, Alvera Analyzing the impact of rapid diagnostics xpert mTB|rif in Western Cape South Africa. Gains or financial burden?

P07 Sakashita, Kentaro; Takeuchi, Rikiya

Mpt64 detection in sputum with an ultrasensitive enzyme-linked immunosorbent assay to evaluate the viability of mycobacterium tuberculosis

P08 Shepelkova, Galina Micrornas expression in post primary tuberculosis patients' serum

P09 Mohamed, Sagal Overview of commercial targeted genotypic drug susceptibility testing assays for m. Tuberculosis complex

P10 Portevin, Damien Cellular biomarker assay for diagnosis and control of childhood tuberculosis

P11 Andama, Alfred Methyl nicotinate and methyl para-anisate as breath biomarkers for tuberculosis diagnosis: a pilot study in Kampala Uganda

P12 Hoffner, Sven Mflodx® minimdr-TB an innovative rapid diagnostic test for multidrug-resistant tuberculosis

P13 Starshinova, Anna New immunologic tests in diagnosis of tuberculosis infection in children of different age

P14 Uwimaana, Esther Heme oxygenase-1 and neopterin plasma|serum levels and their role in diagnosing latent TB and active TB among HIV|TB co-infected patients

P15 Massou, Faridath; Affolabi, Dissou

Culture free approaches for the diagnostic and management of patients with drug resistant tuberculosis: the DIAMA project

P16 Murase, Yoshiro Development of one-day drug susceptibility testing by monitoring mpt64 antigen secreted from mycobacterium tuberculosis

POSTER NUMBER


P17 Nguyen, Thi Bich Phuong The role of digital chest radiography and genexpert mTB|rif in community-wide active case finding for tuberculosis

P18 Shrivastava, Kamal Rapid molecular assay to differentiate between mycobacterium tuberculosis complex and nontuberculous mycobacteria in clinical samples

P20 Rishi Gupta Systematic validation of blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective diagnostic accuracy study

P21 Quazi, Toufique Impact of fnac implementation at primary healthcare level to improve diagnosis and treatment of tubercular-lymphadenitis to improve case-detection in remote districts of India

P22 Meier, Noemi Rebecca Novel antigens for the diagnosis of tuberculosis in human immunodeficiency virus-infection: a pilot study of patients within the swiss HIV cohort

P23 Beutler, Markus Head to head comparison of analytical sensitivities of bd maxt mdr-TB xpert® mTB|rif ultra and fluorotype® mTB using human and artificial sputum

P24 Esmail, Aliasgar An exhaled-breath screening test for the detection of active pulmonary tuberculosis in patients presenting to primary health care clinics in Cape Town South Africa.

P25 Beutler, Markus Clinical evaluation of a cartridge based dna extraction method for fluorotype® mTB

P26 Srinivasan, Sreenidhi A defined antigen skin test for bovine tuberculosis that can differentiate BCG-vaccinated from infected animals

P27 Der, Joyce Tuberculosis symptoms screening practices of healthcare workers in a district hospital in Ghana

P28 Joseph, Lavania Prevalence of linezolid resistance and associated mutations amongst pre-xdr and xdr isolates requiring drug susceptibility testing at the south african national TB reference laboratory

P29 Connelly, John Clinical performance of prototype point-of-care TB lipoarabinomannan (lam) test in Uganda

P30 Singh, D V Comparative analysis of detection and drug resistance profiling of mycobacterium tuberculosis by conventional and Nanopore sequencing

P31 Randall, Philippa Same day tools including Xpert Ultra and unstimulated IFN-gamma for the rapid diagnosis of pleural tuberculosis – a prospective observational study

POSTERS NEW DIAGNOSTICS TO REACH THE MISSING MILLIONS

15TBSCIENCE 201914 TBSCIENCE 2019

POSTERS NEW DIAGNOSTICS TO REACH THE MISSING MILLIONS

POSTER NUMBER


P32 Manga, Selene Animal model inducing inflammatory regulation process using cannabinoids at the alveolar macrophage membrane level before initial replication of m. tuberculosis pulmonary infection

P33 Apolisi, Ivy Implementing an enhanced case finding strategy for children and adolescents exposed to rifampicin-resistant tuberculosis: lessons from Khayelitsha South Africa

P34 Quinn, Fred Ferret tuberculosis co-infection and transmission model

P35 Mathur, Shubhita An attenuated quadruple gene mutant of mycobacterium tuberculosis imparts protection against tuberculosis in guinea pigs

P36 Mathur, Shubhita Bioa mutant of mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs

P37 Fekadu Assebe, Lelisa Economic burden and incidence of catastrophic expenditure of TB diseases in Ethiopia.

P38 Rikhi, Nimisha Immunization of mice with ethanol-killed mycobacterium tuberculosis generated monoclonal antibodies against cell wall peptidoglycan

P39 Tamene, Wegene Elevated expression of chemokine and adhesion receptors on monocyte subsetsin in TB and HIV

P40 Keicho, Naoto Whole blood mirnas: search for biomarkers of tuberculosis infection leading to disease development

P41 Rush, Catherine Can blood leucocyte immunophenotyping help explain the high burden of extra pulmonary tuberculosis in regional Papua New Guinea?

P42 Bimba, John Timeliness and pattern of drug resistance tuberculosis: line probe assay (lpa) in North-Central Nigeria

P43 Neela, Venkata Sanjeev Kumar

T cell subsets and cytokines in HIV+ individuals with latent and active tuberculosis

P44 Dinkele, Ryan The capture and visualization of live mycobacterium tuberculosis bacilli from tuberculosis-patient bio-aerosols

P45 Devalraju, Kamakshi Prudhula

Defective monocyte signaling pathway in HIV+ individuals with latent tuberculosis infection

P46 Weerasuriya, Chathika How might novel vaccines for prevention of tuberculosis disease impact multidrug resistant tuberculosis burden? A mathematical modelling based analysis of epidemiologic and health economic impact

P47 Hoffmann, Harald Screening of health care workers in kyrgyz TB-hospitals with quantiferon-TB gold plus - surprisingly high lTBi rates among staff of labs and drug resistant TB


POSTER NUMBER


P48 Narayanan, Shridhar Fndr-20081- a novel pre-clinical candidate for treatment of TB|mdr tuberculosis

P49 Reuter, Anja All oral short-course regimens for the treatment of rr-TB: early experiences from Khayelitsha South Africa

P50 Reuter, Anja Responding to the substance use challenge in rifampicin-resistant tuberculosis: preliminary outcomes of a primary health care substance use management model in Khayelitsha South Africa

P51 AL-Hajoj Al-Nakhli, Sahal Multidrug resistant mycobacterium tuberculosis strains in Saudi Arabia: myth reality and worldwide impact

P52 Testov, Vadim Adverse reactions in treatment of mdr|xdr TB patients with viral hepatitis

P53 de Jong, Bouke Smear-based monitoring of first-line tuberculosis treatment in Mali: challenges with early identification of initial rifampicin resistance and true treatment failure

P54 Kazakov, Alexey Genome-wide sequencing using biological chips in children and adolescents with tuberculosis

P55 Chung, Chiwook A successful bedaquiline salvage therapy on mycobacterium intracellulare lung disease

P56 Adanan, Norshamiera Antimicrobial potential of metabolites from mangrove actinobacteria against tuberculosis (TB) surrogate mycobacteria

P57 Mishra, Richa Clinical characteristics second line drug susceptibility results and treatment outcome among patients with multidrug -resistant tuberculosis

P58 Abila, Derrick Bary Prevalence of adverse drug reactions to co-trimoxazole among TB|HIV co-infected patients attending care at mulago national referral hospital art clinic

P59 Nyang'wa, Bern-Thomas Using an optimal design approach to efficiently design a pkpd study of multiple anti-TB drugs regimens: experience from the practecal-pkpd study

P60 Mapiye, Darlington Application of machine learning for phenotypic prediction of drug-resistant tuberculosis from whole genome sequencing data

P61 Anejo-Okopi, Joseph Poor intra-facility referral linkages: a missed opportunity for tuberculosis case detection and treatment in north-central Nigeria

P62 Elduma, Adel Causal method to estimate the effects of previous tuberculosis treatment in multidrug-resistant tuberculosis in sudan: case control study

POSTERS PREVENT INFECTION OR PREVENT DISEASE?

POSTERS NEW STRATEGIES IN TB THERAPEUTICS: IT’S TIME TO BREAK THE MOULD!


POSTER NUMBER


P63 Elduma, Adel Antioxidant supplementation to improve oxidative stress and outcome of chemotherapy in patients of smear positive pTB

P64 Saini, Vinay Development and characterization of metered dose inhaler (mdi) formulations for drug sensitive and mdr tuberculosis.

P65 Kloprogge, Frank Pharmacodynamic drug-drug interactions of the isoniazid-rifampicin backbone for treatment of drug sensitive tuberculosis

P66 Agnarson, Abela Mpobela Long-term impact of adoption of bedaquiline-containing regimens on drug-resistant tuberculosis burden in China

P67 Anejo Okopi, Joseph Evaluation of markers of clinical improvement among HIV infected adults treated for tuberculosis in jos North-Central Nigeria: a restrospective cohort study

P68 Agnarson, Abela Mpobela; Dhir, Amit

Long-term impact of adoption of bedaquiline regimens on drug-resistant tuberculosis burden in Indonesia

P69 Operario, Darwin Pharmacogenetic analysis of drug metabolism polymorphisms from saliva of patients treated for tuberculosis in East Africa

P70 Kaur, Dashleen Analyzing rv3083 of mycobacterium tuberculosis as a potential drug target

P72 Bhalla, Manpreet Evaluation of moxifloxacin and levofloxacin by mgit960 drug susceptibility testing for management of retreatment cases of tuberculosis- a comparative study

P73 Mallikaarjun, Suresh Feasibility of once-a-day dosing of delamanid based on pk|pd analysis

P74 van Kampen, Sanne; Jones, Rupert

Outcomes of pulmonary rehabilitation in four countries on three continents

P75 Sambu, Cheruiyot Nutrition status among TB|HIV co-infected patients attending Kapkatet county hospital Kericho county Kenya

P76 Rzhepishevska, Olena Evaluation of treatment progress in tuberculosis patients based on their serum metabolite profiles

P77 Millard, James Characterisation of pyrazinamide minimum inhibitory concentrations and pnca sequencing amongst rifampicin-resistant tuberculosis isolates in Kwazulu-Natal South Africa

P78 Hlaka, Lerato Minor groove binders as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a drug delivery systems for pathogen-directed drug therapy for

POSTER NUMBER


P79 Lerato Hlaka Il-4i1 regulates macrophage mediated immune responses to acute mycobacterium tuberculosis infection

P80 Lerato Hlaka A smart approach to reversing drug resistance in TB and deploying the hidden potential of current TB drugs

P81 Li, Yang Optimizing the shorter regimen for multidrug-resistant tuberculosis patients with molecular drug sensitivity testing: fewer shorter better




POSTER NUMBER


P82 Huang, Chuan-Chin The genetic profile of drug resistance and TB history

P83 Sembulingam, Tamilzhalagan

Potentially missed drug-resistant mutations amongst dr-TB persons living in Chennai, India

P84 Bello Abubakar, Usman Diagnosis of zoonotic mycobacterium africanum transmission between human and cattle: a case report

P85 N’Dira, Sanoussi Association of mycobacterium africanum infection with slower disease progression and low body mass index compared to mycobacterium tuberculosis in malian patients with tuberculosis

P86 Ergeshov, Atadzhan Evolution of spread of m. tuberculosis with different genetic determinants of resistance to fluoroquinolones (based on the population in Russia for the period of 2014-2018)

P87 Murase, Yoshiro Genome TB epidemiology from national prevalence survey in Mongolia

P88 Yeboah-Manu, Dorothy Population-based molecular epidemiological study identifies transmission hotspot and a high rate of relapse among recurring TB cases in Accra, Ghana

P89 Das, Samir Need to consider zoonotic tuberculosis and other mycobacterial infections to curb tuberculosis through one health stewardship

P90 Velen, Kavindhran Comparison of tuberculosis (TB) yield and risk factors among household contacts of persons with drug-resistant and drug-susceptible TB in South Africa

P91 Fu, Lijuan Genetic composition and evolution of the prevalent mycobacterium tuberculosis lineages 2 and 4 in the Chinese and Zhejiang population

P92 Ektefaie, Yasha Phylogenetic analysis of globally representative myobacterium tuberculosis whole genome sequences identifies geographically distinct patterns of drug resistance evolution

P93 Mujuni, Dennis Time to sputum culture conversion among multi-drug-resistant patients referred to the Uganda national|supranational tuberculosis reference laboratory between June 2017 and December 2018

P94 Ofori-Anyinam, Boatema Energy metabolism in the mycobacterium tuberculosis complex: the case of evolutionary convergence in the electron transport chain and central carbon metabolic pathway

P95 Chongsuvivatwong, Virasakdi

The genetic spatial analysis of mycobacterium tuberculosis in tuberculosis hot and cold spots of Guangxi China

POSTER NUMBER


P96 Warner, Digby Catching bacilli in flight: direct sampling and analysis of mycobacterium tuberculosis aerosols

P97 Koch, Anastasia Culture-independent whole genome sequencing mTB isolates directly reveals within-patient heterogeneity

P98 Cirillo, Daniela Maria Intramacrophagic expression profile of the smallrna ncrv0757c in different m. tuberculosis lineages

POSTERS BACTERIAL EVOLUTION

POSTERS BACTERIAL EVOLUTION

POSTERS MAP

22 TBSCIENCE 2019

SEATING AREA

JOIN US IN SEVILLE 20 – 21 OCTOBER 2020

TUESDAY 29 OCTOBER

P01-P31 10.00 – 10.25 New Diagnostics to reach the missing millions

P01-P31 12.30 – 13.00 New Diagnostics to reach the missing millions

P32-P47 13.00 – 13.30 Prevent infection or prevent disease?

P32-P47 15.00 – 15.30 Prevent infection or prevent disease?

WEDNESDAY 30 OCTOBER

P48-P81 10.00 – 10.20 New strategies in TB therapeutics: It’s time to break the mould!

P48-P81 12.30 – 13.00 New strategies in TB therapeutics: It’s time to break the mould!

P82-P98 13.00 – 13.30 Bacterial Evolution

P82-P98 15.00 – 15.30 Bacterial Evolution

P01-P31

P32-P47

P48-P81

P82-P98

E D C T P

29–30 october 2019 hyderabad, india€¦ · at the hyderabad international convention centre...

Documents